166 related articles for article (PubMed ID: 36632739)
1. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
Song JY; Nwangwu M; He TF; Zhang W; Meawad H; Bedell V; Murata-Collins J; Skrabek P; Nasr MR; Scott D; Godfrey J; Lee P; Chan WC; Weisenburger DD; Perry AM; Herrera AF
Haematologica; 2023 Aug; 108(8):2167-2177. PubMed ID: 36632739
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
5. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
Autio M; Leivonen SK; Brück O; Mustjoki S; Mészáros Jørgensen J; Karjalainen-Lindsberg ML; Beiske K; Holte H; Pellinen T; Leppä S
Haematologica; 2021 Mar; 106(3):718-729. PubMed ID: 32079690
[TBL] [Abstract][Full Text] [Related]
6. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.
Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L
Front Immunol; 2023; 14():1230017. PubMed ID: 37790933
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
8. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.
Croci GA; Au-Yeung RKH; Reinke S; Staiger AM; Koch K; Oschlies I; Richter J; Poeschel V; Held G; Loeffler M; Trümper L; Rosenwald A; Ott G; Spang R; Altmann B; Ziepert M; Klapper W
Ann Oncol; 2021 Nov; 32(11):1400-1409. PubMed ID: 34438040
[TBL] [Abstract][Full Text] [Related]
9. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
[TBL] [Abstract][Full Text] [Related]
10. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
11. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
12. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
[TBL] [Abstract][Full Text] [Related]
13. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
14. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
15. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.
Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA
Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529
[TBL] [Abstract][Full Text] [Related]
16. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
[TBL] [Abstract][Full Text] [Related]
17. High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
Liu X; Zhao X; Yang J; Wang H; Piao Y; Wang L
Eur J Haematol; 2023 Feb; 110(2):198-208. PubMed ID: 36335584
[TBL] [Abstract][Full Text] [Related]
18. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
19. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
